L. Korkmaz Et Al. , "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?," American journal of perinatology , vol.39, no.2, pp.204-215, 2022
Korkmaz, L. Et Al. 2022. Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?. American journal of perinatology , vol.39, no.2 , 204-215.
Korkmaz, L., Ozdemir, A., Pamukçu, Ö., Güneş, T., & Ozturk, M., (2022). Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?. American journal of perinatology , vol.39, no.2, 204-215.
Korkmaz, LEVENT Et Al. "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?," American journal of perinatology , vol.39, no.2, 204-215, 2022
Korkmaz, LEVENT Et Al. "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?." American journal of perinatology , vol.39, no.2, pp.204-215, 2022
Korkmaz, L. Et Al. (2022) . "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?." American journal of perinatology , vol.39, no.2, pp.204-215.
@article{article, author={LEVENT KORKMAZ Et Al. }, title={Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?}, journal={American journal of perinatology}, year=2022, pages={204-215} }